Mizuho Securities Upgrades Sage Therapeutics (SAGE) to Buy; BIIB Deal Provides 'External Validation'
Tweet Send to a Friend
(Updated - December 4, 2020 4:44 AM EST)(updating comment)Mizuho Securities analyst Vamil Divan upgraded Sage Therapeutics (NASDAQ: SAGE) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
